Serologic evidence for early SARS-CoV-2 circulation in Lima, Peru, 2020.

- Andres Moreira-Soto*1,2, Maria Paquita García3*, Gloria Arotinco-Garayar3, Dana 3
- Figueroa-Romero³, Nancy Merino-Sarmiento³, Adolfo Marcelo-Ñique³, Edward 4
- Málaga-Trillo⁴, César Cabezas Sanchez³ and Jan Felix Drexler^{1,5#} 5
- ¹Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 7
- Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany 8
- ²Tropical Disease Research Program, School of Veterinary Medicine, Universidad 9
- 10 Nacional, Costa Rica, Costa Rica

2

6

- ³National Institute of Health–INS (Instituto Nacional de Salud–INS), Lima, Peru 11
- ⁴Universidad Peruana Cayetano Heredia, Facultad de Ciencias y Filosofía, 12
- 13 Laboratorios de Investigación y Desarrollo, Lima, Perú
- ⁵German Centre for Infection Research (DZIF), associated partner Charité-14
- Universitätsmedizin Berlin, Berlin, Germany 15
- *These first authors contributed equally 16
- #corresponding author 17
- Correspondence: Professor Dr. Jan Felix Drexler, Institute of Virology, Charitéplatz 1, 18
- 10117 Berlin, Germany, Tel.: +49 30 450 625461/Fax: +49 30 450 7525907, 19
- felix.drexler@charite.de 20

21

- 22 Running Title:
- 23 Dissemination of SARS-CoV-2 in Peru, early 2020
- 25 Keywords:

24

27

28

29

30

31

32

33

34

35

36

37 38

39 40

41

42 43

44

45

46 47

48

49

50

51

52

26 SARS-CoV-2, COVID-19, Peru, pandemic, Latin America, serology, antibodies

Abstract

During early 2021, Peru had the highest COVID-19-associated per-capita mortality rate globally. Socioeconomic inequality and insufficiently prepared healthcare and surveillance systems likely contributed to high mortality, potentially coupled with early SARS-CoV-2 introduction. We tested 1,441 individuals with fever sampled during August 2019-May 2021 in Lima, Peru, for SARS-CoV-2-specific antibodies. Serologic testing included a chemiluminescence immunoassay and confirmatory surrogate virus neutralization testing. Early positive samples (n=24) from January-March 2020 were further tested using a plaque-reduction neutralization and avidity tests based on SARS-CoV-2 spike and nucleoprotein antigens. None of the early samples were PRNT-confirmed, in contrast to 81.8% (18/22) of a subsample from April 2020 onwards (Fischer-exact test, p<0.0001). SARS-CoV-2 antibody detection rate was 0.9% in mid-April 2020 (1/104; 95% confidence interval (CI), 0.1-5.8%), suggesting onset of viral circulation in early-mid March 2020, consistent with the first molecular detection of SARS-CoV-2 in Peru on March 6th. Mean avidity increase of 62-77% to 81-94% from all PRNT-confirmed samples during early 2020, were consistent with onset of SARS-CoV-2 circulation during late February/March 2020. Early circulation of SARS-CoV-2 was confirmed in a Susceptible, Exposed, Infected and Recovered mathematical model that projected an effective reproduction number >1, during February-March 2020. Robust serologic testing thus confirmed that early SARS-CoV-2 introduction contributed to high COVID-19 mortality in Peru. Emphasizing the role of diagnostic confirmation, our study highlights the importance of early detection and accurate testing in managing infectious disease outbreaks.

Importance

Latin America was hard hit by the COVID-19 pandemic. Reasons include inadequate healthcare preparation and socio-economic vulnerabilities, likely exacerbated by early undetected SARS-CoV-2 circulation. Diagnostic testing for early SARS-CoV-2 circulation requires exhaustive diagnostic validation due to unspecific reactivity. We used a cohort of circa 1400 febrile patients from August 2019 until May 2021, months earlier than the first seroprevalence study in Lima, Peru, using a two-step diagnostic algorithm. Early 2020 positive samples were further tested with neutralization tests and avidity testing. We confirmed SARS-CoV-2-specific antibodies from April 2020 onwards, suggesting undetected viral circulation circa March 2020, consistent with the first SARS-CoV-2-detection. Early circulation was further confirmed by the significant increase in avidity in positive samples during early 2020 and the modeled peak of reproduction number of >1 during February-March 2020. Using exhaustive diagnostic validation, we detected early SARS-CoV-2 circulation that likely contributed to the severe impact of COVID-19 in Peru.

The first cases of COVID-19 were detected in China in mid-December 2019, followed by detections elsewhere in Asia and North America during January 2020 and in Europe during February 2020 (1). The first COVID-19 case in Latin America was detected in Brazil on February 26th, 2020 (1). Despite hosting only 8.5% of the world's population, Latin America accounted for 30% of COVID-19 deaths worldwide (2). Within Latin America, Peru had the highest per-capita mortality rate both regionally and globally (1, 3). Tentative explanations for the high Peruvian mortality rate have included poorly prepared healthcare systems, genetic predisposition, comorbidities, social inequality and poverty, difficulties following quarantine measures, frequent informal labour, and lack of surveillance systems leading to inaccurate mortality estimates (4). Early SARS-CoV-2 circulation might be a contributing factor to high mortality in Peru.

We investigated SARS-CoV-2-specific IgG antibodies in 1,441 individuals with acute febrile illness investigated between August 2019-May 2021 in the capital city of Lima (**Figure 1A**) by the Peruvian reference laboratory, allowing retrospective analyses several months prior to the first seroprevalence study available from Lima conducted April 2020 (5). The subpopulation consisted of 49.8% females and 50.1% males, with a mean age of 33.7 years and a standard deviation of 20.3 years, comparable to census data from Lima (48.6% males and 51.4% females; mean age=26) (https://censo2017.inei.gob.pe/).

Approximately 50% of Peruvian seroprevalence studies have a high risk of bias due to the use of potentially non-specific diagnostic tests affected by co-circulating pathogens such as dengue virus (DENV) and *Plasmodium* (**Figure 1B**) (5-7). For confirmation, we used a 2-step testing algorithm including a chemiluminescence immunoassay (CLIA) (SARS-CoV-2 S-RBD IgG kit; Snibe Diagnostic, China), and confirmatory SARS-CoV-2 surrogate virus neutralization test (sVNT; GenScript, USA), both based on the partial SARS-CoV-2 receptor binding domain. Only samples positive in both assays were considered for further analyses to maximize specificity. Additionally, all positive sera from the first six months of 2020, a confirmatory plaque reduction neutralization test (PRNT) based on a 50% reduction in plaque count was performed at 1/8 serum dilution to allow detection of potentially low antibody titers (6). To differentiate between recent and pre-existing SARS-CoV-2 infections, the antibody-antigen binding affinity of SARS-CoV-2 IgG antibodies was determined by

conducting an avidity assay using SARS-CoV-2 spike (S1)- and nucleoprotein (NCP)-102 based IgG ELISAs (Euroimmun, Germany) with an additional 2M urea washing step 103 between sample incubation and detection in one of the replicates. 104 Several seropositive individuals (n=24) in both CLIA and sVNT were found as early 105 106 as January-March 2020 (Figure 1C and 1D). These samples showed significantly lower CLIA and sVNT reactivity in comparison to samples from April 2020 onward 107 (CLIA t-test=-6.4, p<0.001; sVNT t-test=-10.9, p<0.001) (**Figure 1C** and **1D**). 108 Additionally, these samples showed a statistically higher mean S-based avidity of 109 126.4% and lower NCP-based avidity of 11.0% compared to samples from April 2020 110 onward (S t-test=2.4, p=0.01; NCP t-test=-2.9, p=0.007; Figure 1E and 1F). High 111 avidity to the S protein is reached 1-2 months after SARS-CoV-2 infection and is 112 maintained for approximately 6-8 months (8, 9). High S-based avidity would thus 113 suggest very early SARS-CoV-2 infection in patients sampled during January 2020. 114 contrasting with calculated SARS-CoV-2 phylogenetic introduction estimates and the 115 first SARS-CoV-2 molecular detections in Latin America dating from February 2020 116 onwards (10). Since PRNT is the serological gold-standard, we further tested all 117 SARS-CoV-2 seropositive samples from January-July 2020 (n=46) using PRNT. 118 None of the early samples from January-March 2020 were PRNT-confirmed, in 119 contrast to 81.8% (18/22) samples from April onwards (Fischer-exact test, p<0.0001). 120 However, a study that tested thousands of convalescent plasma samples using 121 PRNT found that nearly one-third of confirmed SARS-CoV-2 patients that resolved 122 infection had little to no neutralizing activity (11), regardless of when the samples 123 were taken after their COVID-19 infection. Therefore, we cannot exclude that the 124 125 PRNT-negative (n=5) CLIA, sVNT and S- NCP-high avidity patients in January-March 2020 might have had a past SARS-CoV-2 infection (Figure 1G). Of note, no sera that 126 127 were CLIA positive in 2019 were sVNT positive, suggesting that a minimum 2-step testing algorithm is needed for accurate SARS-CoV-2 serological diagnostics. As a 128 conservative approach, we decided to exclude non-PRNT confirmed samples from 129 January-March 2020 from subsequent analyses, because unspecific reactivity in 130 CLIA and sVNT in those samples seemed the most plausible explanation. 131 Following diagnostic validation, the SARS-CoV-2 antibody detection rate was 0.9% 132 during April 2020 (1/104; 95% confidence interval (CI), 0.1-5.8%). SARS-CoV-2 133 antibody detection steadily increased reaching 9.7% (9/93; 95% CI: 5.0-17.8%) in 134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

May 2020, reaching a mean of 35% (148/460; 95% CI: 28.0-36.6%) from June afterwards. Given that the mean detection time of SARS-CoV-2-specific IqG antibodies post-symptom onset is 20 days (13), a projected time of infection for the first PRNT-confirmed case could have occurred in early-middle March 2020 which is consistent with the first molecular detection of SARS-CoV-2 in Peru on March 6th (12), 2020 and genomic reconstructions of SARS-CoV-2 in Latin America (10). Avidity to the SARS-CoV-2 NCP and S protein in all PRNT-confirmed CLIA- and sVNT-positive samples from April to July 2020 was high and increased from a mean 77 to 94% for NCP and from 62 to 81% for the S protein by June/July 2020 (NCP ttest=-0.66; p= 0.53; S t-test=-1.12; p= 0.29; **Figure 1E** and **1F**). Those avidity results were thus consistent with onset of SARS-CoV-2 circulation during February/March 2020. Onset of SARS-CoV-2 circulation during February/March in Peru was also in concordance with the increase in reported excess mortality peaking mid-March 2020 (Figure 2A and 2B). Stagnation of antibody detection rate during mid-2020 in our study was likely due to the strict non-pharmaceutical interventions (NPIs) in place since March 2020 and mounted population immunity after a high infection peak (Figure 2B) (14). Limited transmission is supported by a gradual decline in CLIA titers due to gradual decay of SARS-CoV-2 antibodies (15) during 2020 followed by a resurgence in early 2021 (Figure 1D), potentially due to the emergence of antigenic variants such as gamma during early 2021 (1). Notably, resurgence of CLIA titers paralleled an increase in excess mortality and reported COVID-19 cases during early 2021 (Figure 2A). Early viral circulation, stagnation, and resurgence of SARS-CoV-2 infections during early 2021 was confirmed using a Susceptible, Exposed, Infected and Recovered Bayesian model relying on reported cases and antibody detection data from our study (16). The model suggested peak virus circulation, with an effective reproduction number (Reff) >1, during February-March 2020, one to two months before the reported peak incidence and mortality which is plausible given the delay in onset of diagnostics estimated at up to 5 days even in affluent settings (16). The model also reconstructed the decrease in virus circulation after July 2020 and increase during end of 2020 (Figure 2C and 2D).

Our data suggest undetected onset of SARS-CoV-2 circulation in Lima during February-March 2020 homologous to other hard-hit Latin American COVID-19 hot spots; e.g., Brazil and Ecuador (1, 2). Considering the intense connectivity between Europe, USA and Peru, it is likely that SARS-CoV-2 circulated before the first case was officially reported.

Limitations of our study include the analysis of a cohort that is not representative of the general population. However, the unique cohort allowed to retrospectively trace SARS-CoV-2 over time during the onset of the pandemic. Another limitation is analysis of sera from febrile individuals whose acute disease may affect serologic diagnostics of SARS-CoV-2, including Malaria and dengue (6, 7). However, our exhaustive serologic analyses allowed robust detection of SARS-CoV-2-specific antibodies.

Our study suggests that early introduction and substantial circulation likely exacerbated the high COVID-19 associated mortality observed in Peru, irrespective of other effect modifiers. Our work emphasizes the complex SARS-CoV-2 serologic diagnostic confirmation in tropical settings, crucial in understanding the pandemic's trajectory, and highlights the importance of early detection and accurate testing in managing infectious disease outbreaks.

Acknowledgments

References:

- 197 1. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus
- 198 Pandemic (COVID-19). Our World in Data. 2020.
- 199 2. Burki T. COVID-19 in Latin America. Lancet Infect Dis. 2020 May;20(5):547-8.
- 200 3. Lima EEC, Vilela EA, Peralta A, Rocha M, Queiroz BL, Gonzaga MR, et al. Investigating regional
- 201 excess mortality during 2020 COVID-19 pandemic in selected Latin American countries. Genus.
- 202 2021;77(1):30.
- 203 4. Taylor L. Covid-19: Why Peru suffers from one of the highest excess death rates in the world.
- 204 BMJ. 2021 Mar 9;372:n611.
- 205 5. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-
- 206 CoV-2 seroprevalence dashboard. Lancet Infect Dis. 2021 Apr;21(4):e75-e6.
- 207 6. Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. Limited
- 208 Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin. Emerg Infect Dis. 2021
- 209 Jan;27(1):233-7.
- 210 7. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential Antigenic
- 211 Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and
- 212 Dengue Viruses. Clin Infect Dis. 2021 Oct 5;73(7):e2444-e9.
- 213 8. Takahashi E, Sawabuchi T, Homma T, Fukuda Y, Sagara H, Kinjo T, et al. Clinical Utility of
- 214 SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in
- 215 Monitoring Protective Immunity and Clinical Severity. Viruses. 2023 Jul 30;15(8).
- 216 9. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, et al.
- 217 Antibody response to SARS-CoV-2 for more than one year kinetics and persistence of detection are
- 218 predominantly determined by avidity progression and test design. J Clin Virol. 2022 Jan;146:105052.
- 219 10. Candido DS, Claro IM, de Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution and
- 220 epidemic spread of SARS-CoV-2 in Brazil. Science. 2020 Sep 4;369(6508):1255-60.
- 221 11. Zhang S, Ma P, Orzechowski M, Lemmer A, Rzasa K, Bagnall J, et al. High-Throughput
- 222 Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune
- 223 Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March
- and August 2020. mBio. 2023 Apr 25;14(2):e0352322.
- Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in
- patients with coronavirus disease 2019. Clin Transl Immunology. 2020 May;9(5):e01136.
- 227 13. Munayco CV, Tariq A, Rothenberg R, Soto-Cabezas GG, Reyes MF, Valle A, et al. Early
- 228 transmission dynamics of COVID-19 in a southern hemisphere setting: Lima-Peru: February 29th—
- 229 March 30th, 2020. Infectious Disease Modelling. 2020 2020/01/01/;5:338-45.
- 230 14. Moreira-Soto A, Bruno A, de Mora D, Paez M, Garces J, Wulf B, et al. Virological evidence of
- 231 the impact of non-pharmaceutical interventions against COVID-19 in Ecuador, a resource-limited
- 232 setting. Emerg Microbes Infect. 2023 Dec;12(2):2259001.
- 233 15. Vabret N. Antibody responses to SARS-CoV-2 short-lived. Nat Rev Immunol. 2020
- 234 Sep;20(9):519.
- 235 16. Netto EM, Moreira-Soto A, Pedroso C, Höser C, Funk S, Kucharski AJ, et al. High Zika Virus
- 236 Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks. mBio.
- 237 2017 Nov 14;8(6).
- 238 17. Harris JE. Timely epidemic monitoring in the presence of reporting delays: anticipating the
- 239 COVID-19 surge in New York City, September 2020. BMC Public Health. 2022 2022/05/02;22(1):871.




Figure 1. SARS-CoV-2 seroprevalence studies in Peru and diagnostic confirmation. A) Map that shows Peruvian regions where seroprevalence studies have been performed. Data taken from (serotracker.com). B) Seroprevalence studies in Peru, size shows the risk of bias calculated by serotracker, lines connecting the dots show the total study time. C) Reactivity of serum samples to SARS-CoV-2 in a SARS-CoV-2 surrogate virus neutralization test (sVNT), shown in the x axis, and a chemiluminescence immunoassay (CLIA), shown in the y axis. AU/ml, absorbance unit per milliliter. Triangles show early samples that were positive in a plaque reduction neutralization test (PRNT), Big circles show samples that were negative in

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

PRNT. D) CLIA concentration across time in the tested samples. The red line denotes the mean CLIA concentration per month. Gray lines denote the 95% confidence interval. Triangles show early samples that were positive in a plague reduction neutralization test (PRNT). Big circles show samples that were negative in PRNT, AU/ml; absorbance units per millilitre. E) IgG antibody avidity index against SARS-CoV-2 S and NCP antibodies overtime in PRNT-positive and negative early 2020 samples. Horizontal line denotes the index thresholds of >60% (positive) and <40% (negative) results between these values are considered borderline, as defined by the manufacturer (https://www.euroimmun.com). Gray area denotes the 95% confidence interval. F) Boxplots showing the median avidity by a bar, quartiles by boxes, and minimum and maximum by whiskers. Above, p values of a t-test. G) Reactivity of six serum samples that were SARS-CoV-2 PRNT-negative but SARS-CoV-2 sVNT and CLIA positive, defined as >30 and >1 respectively, as per manufacturer's instructions. IqG antibody avidity index against SARS-CoV-2 S and NCP antibodies overtime shown in the figure axis, index thresholds of >60% are considered positive as per manufacturer's instructions.




Figure 2. Transmission dinamics of SARS-CoV-2 in Lima, Peru. A) Reported excess mortality. The line shows the monthly reported excess mortality during the study period. Mortality data taken from: <a href="https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-normalization-de-salud-normal

274

275

276

277

278

279

280

281

282

283

284

minsa-. B) Monthly seropositivity from Lima from this study (dots), gray area represents the 95% confidence interval. Linear regression line is shown in red. C) SEIR model showing the reported incidence data (red dots) and the modeled incidence (gray area) calculated using the reported incidence data and antibody detection rate from this studv. Weekly incidence data taken from (https://www.datosabiertos.gob.pe/dataset/casos-positivos-por-covid-19-ministeriode-salud-minsa). The black line denotes the median modeled incidence, and the gray area denotes the 1st and 3rd quartiles of the modeled incidence. D) Effective reproductive number calculated using the model.